TY - JOUR
T1 - Update on anti-phospholipid antibodies in SLE
T2 - The Hopkins Lupus Cohort
AU - Petri, M.
PY - 2010/4
Y1 - 2010/4
N2 - Anti-phospholipid antibodies are common in patients in the Hopkins Lupus Cohort: 47% have anti-cardiolipin, 32.5% anti-β2-glycoprotein I and 26% lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50% chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infarction. Anti-phospholipid antibodies are not associated with atherosclerosis.
AB - Anti-phospholipid antibodies are common in patients in the Hopkins Lupus Cohort: 47% have anti-cardiolipin, 32.5% anti-β2-glycoprotein I and 26% lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50% chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infarction. Anti-phospholipid antibodies are not associated with atherosclerosis.
KW - Anti-cardiolipin antibodies
KW - Anti-phospholipid syndrome
KW - Lupus anticoagulant
UR - http://www.scopus.com/inward/record.url?scp=77951233843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951233843&partnerID=8YFLogxK
U2 - 10.1177/0961203309360541
DO - 10.1177/0961203309360541
M3 - Review article
C2 - 20353980
AN - SCOPUS:77951233843
SN - 0961-2033
VL - 19
SP - 419
EP - 423
JO - Lupus
JF - Lupus
IS - 4
ER -